Kabelline
Kabelline
Brand
Kabelline
Category
Lipolysis
Origin
Korea
Interested in ordering Kabelline? Send an enquiry and our team will follow up with availability and pricing.
Used in
Overview
Kabelline is a South Korean injectable lipolysis solution built on synthetic deoxycholic acid, marketed for submental and other localized fat reduction. It belongs to the deoxycholic-acid detergent class of fat-dissolving injectables and is supplied for professional use, typically in multi-vial boxes. Supplier listings attribute manufacture to Korean firms (variously Neogenesis and Wellspharmtech), so a single verified maker is not asserted here.
How it works
Deoxycholic acid, a bile-acid detergent, disrupts adipocyte cell membranes and causes adipocytolysis at the injection site. The liberated lipids and cellular debris are cleared by macrophages and the lymphatic system and metabolized over several weeks. The resulting local inflammatory response drives the expected swelling over the first 3-7 days.
Indications
- Submental fat / double chin
- Jawline contouring
- Localized facial fat
- Small stubborn body-fat pockets
- Flanks / love handles
Key features
- Synthetic deoxycholic-acid detergent active
- Submental and localized fat-reduction focus
- Professional-use multi-vial packaging
- Well-recognized Korean fat-dissolving brand
- Same active class as established deoxycholic-acid injectables
Benefits
- Non-surgical option for double chin and small fat pockets
- Recognizable brand supports patient confidence
- Deoxycholic-acid mechanism familiar to practitioners
- Staged protocol suits course-based pricing
- Multi-vial format convenient for enquiry-to-order stocking
Composition
Synthetic deoxycholic acid (with plant-extract adjuncts per supplier listings)
Usage & handling
Inject subcutaneously into the mid-fat plane using a grid pattern (points spaced roughly 1 cm), keeping per-point volumes conservative (around 0.2 mL), and stage sessions about 3-4 weeks apart. Deoxycholic acid is a potent detergent: avoid superficial injection to reduce dermal/skin-necrosis risk, and inject with precision away from the marginal mandibular nerve when treating the submental area. Expect swelling for 3-7 days.
For medical professionals. Product information is for reference and does not replace the manufacturer's instructions for use. Availability and regulatory status vary by region.